{"id":381788,"date":"2020-11-16T09:03:24","date_gmt":"2020-11-16T14:03:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=381788"},"modified":"2020-11-16T09:03:24","modified_gmt":"2020-11-16T14:03:24","slug":"personalis-to-present-at-the-amp-annual-meeting-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/","title":{"rendered":"Personalis\u00ae to Present at the AMP Annual Meeting 2020"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p>\nPersonalis<sup>\u00ae<\/sup> to Present at the AMP Annual Meeting 2020\n<\/p>\n<p>MENLO PARK, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test &#8211; NeXT Dx<sup>TM<\/sup> &#8211; at the virtual AMP Annual Meeting from Nov 16-20, 2020.\n<\/p>\n<p>\nThe poster presentation, titled \u201cAn exome and transcriptome based NeXT Dx<sup>TM<\/sup> test enables therapy selection for cancer patients and offers insights into emerging composite biomarkers for immunotherapy\u201d will be presented on Tuesday, Nov 17<sup>th<\/sup> between 1-2pm EST. The <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2Fproducts%2Fnext-dx-test%2F&amp;esheet=52328137&amp;newsitemid=20201116005468&amp;lan=en-US&amp;anchor=NeXT+Dx+test&amp;index=1&amp;md5=32a314dc0efab3624c86679396a90d80\">NeXT Dx test<\/a> utilizes Personalis\u2019 <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2Fimmunoid-next-platform%2F&amp;esheet=52328137&amp;newsitemid=20201116005468&amp;lan=en-US&amp;anchor=ImmunoID+NeXT+Platform&amp;index=2&amp;md5=b7079a61a063aae01615ed3ef6a68bca\">ImmunoID NeXT Platform<\/a><sup>\u00ae<\/sup>, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The Personalis NeXT Dx Test provides a diagnostic report to the ordering provider which includes genomic alterations identified in 247 cancer-related genes, therapy recommendations, clinical trial matching and results from immunotherapy-related biomarkers such as microsatellite instability (MSI) status and exome-wide tumor mutational burden (TMB). Research data supporting identification of novel biomarkers from tumor exome and transcriptome can be provided upon physician\u2019s request.\n<\/p>\n<p><b>About Personalis, Inc. <\/b><\/p>\n<p>\nPersonalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient\u2019s cancer and immune response. The Personalis <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2Fimmunoid-next-platform%2F&amp;esheet=52328137&amp;newsitemid=20201116005468&amp;lan=en-US&amp;anchor=ImmunoID+NeXT+Platform&amp;index=3&amp;md5=b9f81e2fbdcd0c8f7204f1023b00ffeb\">ImmunoID NeXT Platform<\/a><sup>\u00ae<\/sup> is designed to adapt to the complex and evolving understanding of cancer, providing our biopharmaceutical customers with information on approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2Fabout%2Flaboratory%2F&amp;esheet=52328137&amp;newsitemid=20201116005468&amp;lan=en-US&amp;anchor=Clinical+Laboratory&amp;index=4&amp;md5=561732164bf4e91fc6b375b145cb041e\">Clinical Laboratory<\/a> is GxP-aligned as well as CLIA\u201988-certified and CAP-accredited. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2F&amp;esheet=52328137&amp;newsitemid=20201116005468&amp;lan=en-US&amp;anchor=www.personalis.com&amp;index=5&amp;md5=c9fa26ccf1cf243d7221f9dd5f176dd6\">www.personalis.com<\/a> and follow Personalis on Twitter (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FPersonalisInc&amp;esheet=52328137&amp;newsitemid=20201116005468&amp;lan=en-US&amp;anchor=%40PersonalisInc&amp;index=6&amp;md5=4993b4c5bcca714789ea01eafc0610b5\">@PersonalisInc<\/a>).\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements in this press release that are not historical are \u201cforward-looking statements\u201d within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis\u2019 services for the VA MVP, the company\u2019s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis\u2019 filings with the U.S. Securities and Exchange Commission, including the company\u2019s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption \u201cRisk Factors.\u201d Personalis disclaims any obligation to update such forward-looking statements.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201116005468\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201116005468\/en\/<\/a><\/span><\/p>\n<p>\nInvestor Relations Contact:<br \/>\n<br \/>Caroline Corner<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:investors@personalis.com\">investors@personalis.com<br \/>\n<\/a><br \/>415-202-5678\n<\/p>\n<p>\nMedia Contact:<br \/>\n<br \/>Jennifer Havlek<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:pr@personalis.com\">pr@personalis.com<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2F&amp;esheet=52328137&amp;newsitemid=20201116005468&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.personalis.com%2F&amp;index=7&amp;md5=696a6556a65d94c1cc27bf395ea30fa2\">https:\/\/www.personalis.com\/<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201116005468\/en\/839035\/3\/PersonalisLogo-RGB-no-tagline.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Personalis\u00ae to Present at the AMP Annual Meeting 2020 MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test &#8211; NeXT DxTM &#8211; at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster presentation, titled \u201cAn exome and transcriptome based NeXT DxTM test enables therapy selection for cancer patients and offers insights into emerging composite biomarkers for immunotherapy\u201d will be presented on Tuesday, Nov 17th between 1-2pm EST. The NeXT Dx test utilizes Personalis\u2019 ImmunoID NeXT Platform\u00ae, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The Personalis NeXT Dx Test &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Personalis\u00ae to Present at the AMP Annual Meeting 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-381788","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Personalis\u00ae to Present at the AMP Annual Meeting 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Personalis\u00ae to Present at the AMP Annual Meeting 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Personalis\u00ae to Present at the AMP Annual Meeting 2020 MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test &#8211; NeXT DxTM &#8211; at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster presentation, titled \u201cAn exome and transcriptome based NeXT DxTM test enables therapy selection for cancer patients and offers insights into emerging composite biomarkers for immunotherapy\u201d will be presented on Tuesday, Nov 17th between 1-2pm EST. The NeXT Dx test utilizes Personalis\u2019 ImmunoID NeXT Platform\u00ae, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The Personalis NeXT Dx Test &hellip; Continue reading &quot;Personalis\u00ae to Present at the AMP Annual Meeting 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T14:03:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Personalis\u00ae to Present at the AMP Annual Meeting 2020\",\"datePublished\":\"2020-11-16T14:03:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/\"},\"wordCount\":517,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/\",\"name\":\"Personalis\u00ae to Present at the AMP Annual Meeting 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-16T14:03:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-to-present-at-the-amp-annual-meeting-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Personalis\u00ae to Present at the AMP Annual Meeting 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Personalis\u00ae to Present at the AMP Annual Meeting 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/","og_locale":"en_US","og_type":"article","og_title":"Personalis\u00ae to Present at the AMP Annual Meeting 2020 - Market Newsdesk","og_description":"Personalis\u00ae to Present at the AMP Annual Meeting 2020 MENLO PARK, Calif.&#8211;(BUSINESS WIRE)&#8211; Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test &#8211; NeXT DxTM &#8211; at the virtual AMP Annual Meeting from Nov 16-20, 2020. The poster presentation, titled \u201cAn exome and transcriptome based NeXT DxTM test enables therapy selection for cancer patients and offers insights into emerging composite biomarkers for immunotherapy\u201d will be presented on Tuesday, Nov 17th between 1-2pm EST. The NeXT Dx test utilizes Personalis\u2019 ImmunoID NeXT Platform\u00ae, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The Personalis NeXT Dx Test &hellip; Continue reading \"Personalis\u00ae to Present at the AMP Annual Meeting 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-16T14:03:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Personalis\u00ae to Present at the AMP Annual Meeting 2020","datePublished":"2020-11-16T14:03:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/"},"wordCount":517,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/","name":"Personalis\u00ae to Present at the AMP Annual Meeting 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-16T14:03:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201116005468r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-to-present-at-the-amp-annual-meeting-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Personalis\u00ae to Present at the AMP Annual Meeting 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381788","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=381788"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/381788\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=381788"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=381788"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=381788"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}